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httpEvaluation of the redesigned conformable GORE
TAG thoracic endoprosthesis for traumatic aortic
transection
Mark A. Farber, MD,a Joseph S. Giglia, MD,b Benjamin W. Starnes, MD,c Scott L. Stevens, MD,d
Jeremiah Holleman, MD,e Rabih Chaer, MD,f and Jon S. Matsumura, MD,g on behalf of the TAG 08-02
clinical trial investigators, Chapel Hill, NC; Cincinnati, Ohio; Seattle, Wash; Knoxville, Tenn; Charlotte, NC;
Pittsburgh, Pa; and Madison, Wisc
Objective: To evaluate the safety and effectiveness of the conformable GORE TAG thoracic endoprosthesis (CTAG) device
(W. L. Gore and Associates, Flagstaff, Ariz) for the endovascular repair of traumatic aortic transections.
Methods: A prospective, nonrandomized, multicenter trial was conducted at 21 sites. Primary safety end points included
30-day all-cause mortality. The effectiveness end point was freedom from a major device event requiring reintervention
through 1-month follow-up.
Results: Fifty-one subjects were enrolled between December 2009 and January 2011 with polytraumatic injuries and
a mean Injury Severity Score of 32 6 14. The proximal mean intimal aortic diameter measured 24 mm, while the mean
distal intimal diameter was 22 mm. A total of 57 CTAG devices were implanted (mean, 1.1/subject; range, 1-2) with
a mean patient age of 44 years (range, 21-87) and a male-to-female ratio of 2:1. Technical success was 100% with an
operative mortality of 0%. Femoral access was utilized in 96% of patients. The mean procedure time and blood loss was
105 minutes and 148 mL, respectively. All subjects required admission to an intensive care unit with a mean hospital stay
of 14.6 days. Adjuvant techniques (ie, lumbar drains and induced hypertension) to prevent paraplegia were used in only
7.8% of patients. No patient developed paraplegia despite 63% having complete or partial left subclavian artery coverage
and only 9% of those receiving left subclavian artery revascularization. In addition, there were no device compressions or
major device events reported. Overall mortality at 30 days was 7.8%, and all were adjudicated by the clinical events
committee as not being device or procedure related. Serious adverse events occurred in 39.2% of patients through 30 days.
To date, there have been no conversions to open repair. Two site-reported endoleaks were detected during the mean
follow-up of 4.2 months, which did not require reintervention.
Conclusions: The CTAG device was demonstrated to be a safe and effective treatment for traumatic aortic transection
based on 30-day outcomes. There were no device-related serious adverse events. (J Vasc Surg 2013;58:651-8.)the Department of Surgery, University of North Carolina, Chapel
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://dx.doi.org/10.1016/j.jvs.2013.02.015The treatment of blunt aortic injury (BAI) has seen
many changes over the last half-century. Despite its not
being approved for this indication, most major trauma
centers began employing its use after thoracic endovascular
aortic repair (TEVAR) approval for aneurysmal disease in
2005.1 By 2010 estimates, more than 64% of injuries
were being managed through endovascular techniques
instead of traditional open repair. It has become recog-
nized that despite its acute beneﬁt in reducing operative
mortality and complications, device complications with
the TAG device (W. L. Gore and Associates, Flagstaff,
Ariz) were occurring that hindered its more universal
acceptance.2,3 Device redesign was therefore necessary to
address these complications that were observed when treat-
ing patients with TEVAR for BAI. The result of these
efforts was an improved stent-graft device: the conformable
GORE TAG thoracic endoprosthesis (CTAG) device
(W. L. Gore and Associates). The primary objective of
this study was to determine the short-term safety and effec-
tiveness of the CTAG device for treatment of subjects with
traumatic aortic transection. This report details the
premarket approval submission data for the treatment of651
Table I. Inclusion and exclusion criteria for the TAG 08-02 study
Inclusion criteria
(1) Traumatic transection of the descending thoracic aorta that requires repair, determined by the treating physician
(2) Traumatic aortic transection location between, but does not include, the left subclavian artery and celiac artery
(3) Endovascular repair with the GORE conformable TAG device performed #14 days after aortic injury
(4) Age $18 years
(5) Proximal and distal landing zone length $2.0 cm
- Landing zones must be in native aorta
- Landing zone may include left subclavian artery, if necessary
(6) All proximal and distal landing zone inner diameters are between 16-42 mm
- Diameter assessed by ﬂow lumen and thrombus, if present; calcium excluded
(7) Subject capable of complying with study protocol requirements, including follow-up
(8) Informed consent form signed by subject or legal representative
Exclusion criteria
(1) Differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for
a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to
compensate for the taper
(2) Tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access
(3) Aneurysmal, dissected, heavily calciﬁed, or heavily thrombosed landing zone(s)
(4) Infected aorta
(5) Subject has a systemic infection and may be at increased risk of endovascular graft infection
(6) Planned coverage of left carotid or celiac arteries with the device
(7) Known degenerative connective tissue disease (eg, Marfan or Ehler-Danlos syndrome)
(8) Treatment in another drug or medical device study within 1 year of study enrollment
(9) Known history of drug abuse
(10) Pregnant female
(11) Moribund patient not expected to live 24 hours with or without operation, determined by the treating physician
(12) ISS of 75
(13) Subject has known sensitivities or allergies to the device materials
ISS, Injury Severity Score.
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Administration (FDA) approval to treat isolated thoracic
aortic lesions.
METHODS
This study was a prospective, multicenter, single-arm
evaluation designed to assess the safety and effectiveness of
the CTAG device in subjects with traumatic aortic transec-
tion. A maximum of 30 investigative sites and 51 subjects
were planned for participation. Lesions were classiﬁed into
one of four categories: intimal tear <1 cm, no hematoma;
tear $1 cm; circumferential disruption; and other. Speciﬁc
inclusion and exclusion criteria are listed in Table I. Subjects
were scheduled for evaluation through hospital discharge
and follow-up visits at 1 month, 6 months, and annually
through 5 years post-treatment. During the 13-month enroll-
ment period, there were four amended protocol changes. The
ﬁrst two changes were used to update imaging guidelines,
whereas the third clariﬁed the deﬁnition of anesthetic classiﬁ-
cation for inclusion and exclusion. The last amendment was
enacted to allow for continued access. This report does not
include data from the patients treated under emergency use
provisions or the continued access arm of the study.
The primary safety end point of this study was all-cause
mortality incidence through 30 days post-treatment.
Subjects who could not be conﬁrmed as alive through30 days postimplant were counted as lost to follow-up.
The primary effectiveness end point was freedom from
any major device event (MDE) requiring reintervention
through the 1-month follow-up visit. An MDE was deﬁned
as endoleak, migration, wire fracture, compression, erosion,
extrusion, aortic dilatation, endograft infection, or aortic
rupture that required signiﬁcant therapy, including
unplanned increase in the level of care, permanent sequelae,
hospitalization, or death per reporting standards.4
Statistical methods. The sample size was determined
assuming a 30-day mortality incidence of 0.10 and was
designed to provide a conﬁdence interval with a half-width
of <0.085. This provides a two-sided 95% score conﬁdence
interval around the estimate of 6 0.084. Statistical calcu-
lations were performed using SAS v. 9.2 (SAS Institute,
Cary, NC).
Device description. The device has undergone speciﬁc
changes from the original TAG device and was based upon
detailed computational analysis surrounding aortic veloci-
ties and anatomy encountered in younger individuals
more likely to be treated with an endoprosthesis for blunt
traumatic aortic injury. Speciﬁc changes include modiﬁca-
tion to the stent frame to increase durability and compres-
sion resistance (change from eight to nine stent apices
around the circumference of the device, increased wire
diameter, and removal of the ﬂares on both the proximal
Fig. GORE TAG device (left) and conformable GORE TAG
device (right).
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stent attachment pattern to enhance conformability of
the device. The Fig depicts the two different iterations of
the device that have received FDA approval.
RESULTS
Eighty-seven patients were screened for enrollment and
36 were excluded for inappropriate landing zones (9), study
informed consent form not signed (8), inability to comply
with protocol follow-up/drug abuse (8), American Society
of Anesthesiologists (ASA) V (4), repair not within 14 days
(3), under 18 years of age (3), and unknown (1). The resul-
tant 51 subjects had polytraumatic injuries and were
enrolled between December 2009 and January 2011 at
21 sites. Seven additional sites were involved with the study
but did not enroll patients.
Subject compliance. Three patients (5.9%) died prior
to their 1-month evaluation, and no subject discontinued
their follow-up (Table II). Computed tomography (CT)
scans were obtained in 93.8% of the eligible patients at 1
month but only 76.7% at the 6-month follow-up interval.
In those patients eligible for their 12-month visit, only one
patient (14.3%) was noncompliant in obtaining an axial
CT scan.
Demographics. There were 34 males and 17 females
enrolled (ratio 2:1) with a mean age for the cohort of
44.1 6 19.9 years (range, 21-87). The majority of patientswere Caucasian (82.4%) and possessed a signiﬁcant medical
history of smoking, hypertension, and/or hypercholester-
olemia (Tables III and IV). The cohort had an ASA clas-
siﬁcation of either III or IV in 80.4% of the patients and
a mean Injury Severity Score (ISS) of 32 6 14 (range,
9-66) (Table V). Fifty of the 51 patients had either a tear
greater than 1 cm, circumferential disruption, or pseu-
doaneurysm. Median time from injury to treatment was
21 hours with a range of 3 to 334 hours. The median
blood pressure upon presentation for the cohort was
130/70 mm Hg. Motor vehicle collision was the etiology
in most patients (84.3%) with 2% of the patients sustaining
their injury from a fall. Table VI comprises a list of the
common concomitant injuries that were predominantly
thoracic in nature. Also included were pulmonary, upper
torso, and extremity fractures.
Aortic and procedure details. The mean intimal
aortic diameter at the proximal implantation site measured
24.1 6 3.7 mm (range, 17-33), whereas the mean distal
intimal diameter was 21.8 6 3.8 mm (range, 16-34).
The average lesion diameter was 29.2 6 6.3 mm (range,
18-47). Mean proximal neck length distal to the left
common carotid artery was 38 mm. Implantation zones
are listed in Table VII. Fifteen patients (29.4%) had
partial left subclavian artery (LSCA) coverage without
revascularization. An additional 17 patients (33.3%) had
complete LSCA coverage with three of these receiving
revascularization (transposition, 1; bypass, 2) at the
discretion of the implanting physician. Patient-speciﬁc
revascularization was physician dependent and the indica-
tion for revascularization was not documented. Snorkels
and chimneys were excluded in the trial. General anesthesia
was used for the procedure in the majority of patients
(92.2%). Femoral access was utilized in 96.1% of patients.
The median external iliac diameter was 8 mm, regardless of
laterality. Percutaneous access was left to discretion of the
investigator and comprised 31.4% of the insertion
methods. There was one iliac artery access exposure and
one infrarenal aortic conduit.
Safety evaluation. A total of 57 CTAG devices
(Table VIII) were implanted (mean, 1.1/subject; range,
1-2) with 88.2% of patients requiring one device for lesion
exclusion (10-cm treated length). Six patients (12%) had
two devices implanted to treat their injury. Reasons for
additional implants included long lesion length in two
subjects, device deployment distal to intended location in
three subjects, and one subject required a second implant
for a presumed type III endoleak. Technical success was
100%, operative mortality was 0%, and no secondary
procedures were required during follow-up. The mean
procedure time and blood loss were 105 minutes and
147.9 mL, respectively. Adjuvant techniques to prevent
paraplegia were used in only 7.8% of patients: cerebrospinal
ﬂuid drainage, 1; hypertension, 2; and steroids, 1. No
patient developed paraplegia, and only one patient with
partial subclavian coverage developed left arm claudication
at 4 months. This was despite 62.7% of the patients having
complete or partial LSCA coverage and only 5.9% receiving
Table II. Subject disposition and compliance by study interval
Study period
Eligible for
follow-up, No.
Follow-up compliance Events prior to next interval
Eligible for
follow-up and
completed
study period,a
No. (%)
Subjects with
visit in
window,a
No. (%)
CT scan
performed,a
No. (%)
X-ray
performed,a
No. (%)
Death,a
No. (%)
Discontinued,a
No. (%)
Not due for
next follow-
up,a No. (%)
Procedure 51 51 (100.0) - - - 0 (0.0) 0 (0.0) 0 (0.0)
Postprocedure 51 51 (100.0) - - - 3 (5.9) 0 (0.0) 0 (0.0)
1 month 48 48 (100.0) 47 (97.9) 45 (93.8) 43 (89.6) 2 (4.2) 0 (0.0) 0 (0.0)
6 months 46 30 (65.2) 26 (56.5) 23 (50.0) 24 (52.2) 1 (2.2) 0 (0.0) 23 (50.0)
12 months 22 7 (31.8) 7 (31.8) 6 (27.3) 6 (27.3) 0 (0.0) 0 (0.0) 22 (100.0)
24 months 0 - - - - - - -
36 months 0 - - - - - - -
48 months 0 - - - - - - -
60 months 0 - - - - - - -
CT, Computed tomography.
Study period deﬁnitions: procedure (0-0 days); postprocedure (1-14 days); 1 month (15-59 days); 6 months (60-242 days); 12 months (243-546 days);
24 months (547-911 days); 36 months (912-1275 days); 48 months (1276-1640 days); 60 months (1641-2006 days).
aPercentages are based on number of subjects eligible for follow-up. Completed study period is deﬁned as any of the following: through window without visit,
death or discontinuation during window, or visit completed in study window.
Table III. Subject demographics
CTAG cohort
Number of enrolled subjects 51
Sex, No. (%)
Male 34 (66.7)
Female 17 (33.3)
Ethnicity, No. (%)
Not Hispanic or Latino 49 (96.1)
Hispanic or Latino 2 (3.9)
Race, No. (%)
White or Caucasian 42 (82.4)
Black or African American 5 (9.8)
Asian/Oriental 2 (3.9)
American Indian or Alaskan Native 1 (2.0)
Native Hawaiian or Other Paciﬁc Islander 1 (2.0)
Age, years
No. 51
Mean (SD) 44.1 (19.9)
Median 40.0
Range 21.0-87.0
CTAG, Conformable GORE TAG thoracic endoprosthesis; SD, standard
deviation.
Table IV. Previous medical history of enrolling subjects
CTAG cohort, No. (%)
Number of enrolled subjects 51
Cigarette smoking 15 (29.4)
Hypertension 13 (25.5)
Hypercholesterolemia 7 (13.7)
CAD 4 (7.8)
Diabetes mellitus 4 (7.8)
COPD 3 (5.9)
CABG 2 (3.9)
Renal insufﬁciency 2 (3.9)
CHF 1 (2.0)
Carotid disease 1 (2.0)
Stroke 1 (2.0)
TIA 1 (2.0)
Peripheral vascular disease 0 (0.0)
CABG, Coronary artery bypass graft; CAD, coronary artery disease; CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease;
CTAG, conformable GORE TAG thoracic endoprosthesis; TIA, transient
ischemic attack.
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deﬁned as any portion of the device proximal to the distal
aspect of the LSCA oriﬁce but not completely occluding
the artery. All patients were admitted to the intensive care
unit and had a mean intensive care unit and hospital stay of
8.2 and 14.6 days, respectively.
Overall mortality at 30 days was 7.8%, and all were
adjudicated by the clinical events committee (CEC) as
not being device or procedure related. Serious adverse
events occurred in 39.2% of patients (Table IX). During
a mean follow-up of 4.2 months, there were no device
compressions, retrograde dissections or MDEs reported;
however, two additional deaths occurred at 57 and 204days related to traumatic brain injury and drug toxicity,
respectively. Neurologic complications were notably absent
beyond the 30-day follow-up interval; however, there were
two reported cerebral events related to hypoxic encepha-
lopathy and an ischemic stroke during the perioperative
time frame. The encephalopathy resolved prior to
discharge in the ﬁrst patient and the remaining patient
with an ischemic stroke died 24 hours after the repair
from splenic hemorrhage. To date, there have been no
conversions to open repair. The primary safety end point
was therefore achieved in 92.2% of cases.
Effectiveness evaluation. No MDEs were reported
for the entire cohort. Two endoleaks were reported. The
ﬁrst involved a site-reported type II endoleak on post-
operative day 14, required no treatment, and was resolved
Table V. Pretreatment risk summary
CTAG cohort
Number of enrolled subjects 51
ASA classiﬁcation, No. (%)
I 5 (9.8)
II 5 (9.8)
III 10 (19.6)
IV 31 (60.8)
V 0 (0.0)
ISS
No. 51
Mean (SD) 31.8 (14.2)
Median 29.0
Range 9.0-66.0
ISS polytrauma, No. (%)
Polytrauma (ISS >17) 43 (84.3)
No polytrauma (ISS #7) 8 (15.7)
Glasgow Coma Scale, No. (%)
Minor $13 41 (80.4)
Moderate 9-12 5 (9.8)
Severe #8 4 (7.8)
Missing 1 (2.0)
ASA, American Society of Anesthesiologists; CTAG, conformable GORE
TAG thoracic endoprosthesis; ISS, Injury Severity Score; SD, standard
deviation.
Table VI. Concomitant injuries reported in >5% of
study subjects
CTAG cohort,
No. (%)
Number of enrolled subjects 51
Any concomitant injury 50 (98.0)
Thoracic cage fractures and dislocations 41 (80.4)
Pneumothorax and pleural effusions NEC 33 (64.7)
Skin injuries NEC 30 (58.8)
Abdominal injuries NEC 24 (47.1)
Spinal fractures and dislocations 23 (45.1)
Upper limb fractures and dislocations 22 (43.1)
Chest and lung injuries NEC 20 (39.2)
Lower limb fractures and dislocations 16 (31.4)
Pelvic fractures and dislocations 16 (31.4)
Parenchymal lung disorders NEC 11 (21.6)
Skull fractures, facial bone fractures and
dislocations
11 (21.6)
Non-site-speciﬁc injuries NEC 8 (15.7)
Hemorrhages NEC 7 (13.7)
Mediastinal disorders 7 (13.7)
Site-speciﬁc injuries NEC 7 (13.7)
Anemias NEC 6 (11.8)
Limb injuries NEC (including traumatic
amputation)
6 (11.8)
Central nervous system hemorrhages and
cerebrovascular accidents
5 (9.8)
Renal and urinary tract injuries NEC 5 (9.8)
Renal structural abnormalities and trauma 5 (9.8)
Urinary abnormalities 5 (9.8)
Vascular hypotensive disorders 5 (9.8)
Adrenal gland disorders NEC 4 (7.8)
Cerebral injuries NEC 4 (7.8)
Paralysis and paresis (excluding cranial nerve) 4 (7.8)
Peritoneal and retroperitoneal hemorrhages 4 (7.8)
Renal vascular and ischemic conditions 4 (7.8)
Respiratory failures (excluding neonatal) 4 (7.8)
Skin and subcutaneous conditions NEC 4 (7.8)
Vascular hypertensive disorders NEC 4 (7.8)
Cardiovascular injuries 3 (5.9)
Pain and discomfort NEC 3 (5.9)
Rate and rhythm disorders NEC 3 (5.9)
Renal failure and impairment 3 (5.9)
Spinal cord and nerve root disorders NEC 3 (5.9)
CTAG, Conformable GORE TAG thoracic endoprosthesis; NEC, not
elsewhere classiﬁed.
Table VII. Zone of device implantation
Zone No. (%)
0 Excluded
1 Excluded
2 32 (63)
3 18 (35)
4 1 (2)
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an investigator-reported type III endoleak (fabric defect),
which was reported to have continued through discharge
despite a secondary device being deployed at the time of
treatment. As a result of the rarity of the event, a CEC
review was undertaken that reached the consensus that it
was an indeterminate endoleak, which was resolved at the
completion of the procedure. Neither the CEC nor the
core lab detected an endoleak at discharge or 1-month
follow-up imaging. Lesion diameter characteristics have
demonstrated no increase in diameter >5 mm during
follow-up based on orthogonal imaging. There have been
no identiﬁed wire frame fractures, compression, obstruc-
tion, or thrombus-related events. There was one core lab-
reported migration of $10 mm at 6 months without
clinical sequelae or impact on lesion exclusion. Subsequent
imaging demonstrated no migration (<10 mm) at 12
months compared with baseline and may be related to
respiratory or imaging variation. The primary effectiveness
end point was achieved in 100% of cases.
DISCUSSION
“Off-label” use of endovascular devices has been occur-
ring for many years and is in excess of 40%.5 Analysis of
outcomes in this patient population has met with mixed
results with poorer outcomes occurring when devices
are implanted in patients with pathologies other than aneu-
rysmal disease.6 BAIs are no exception with endovascular
treatment gaining widespread acceptance despite the lack
of FDA approval and the rigors of a clinical trial. Signiﬁcant
limitations have been reported, however, with the ﬁrst-
generation TEVAR devices when used in treating patientswith BAI.1,7 The most recognized of these limitations is
device collapse.8 Despite the widespread preference over
conventional repair, the potential beneﬁts of TEVAR
over open repair remain controversial.9,10 As with many
other minimally invasive techniques, endovascular manage-
ment of thoracic transections has the potential to reduce
Table VIII. Implanted device sizes
Device size No. (%)
21 5 (8.8)
26  21 11 (19.3)
26 12 (21.1)
28 10 (17.5)
31  26 8 (14.0)
31 5 (8.8)
34 4 (7.0)
37 2 (3.5)
40 0 (0.0)
45 0 (0.0)
Table IX. Summary of serious adverse events through
30 days
CTAG cohort,
No. (%)
Number of enrolled subjects 51
Any serious event 20 (39.2)
Pleural effusion 3 (5.9)
Respiratory failure 3 (5.9)
Anuria 2 (3.9)
Hypotension 2 (3.9)
Hypoxia 2 (3.9)
Ileus 2 (3.9)
Pneumonia 2 (3.9)
Pyrexia 2 (3.9)
Abnormal weight gain 1 (2.0)
Acute respiratory distress syndrome 1 (2.0)
Acute respiratory failure 1 (2.0)
Anemia 1 (2.0)
Angina pectoris 1 (2.0)
Atrial ﬁbrillation 1 (2.0)
Blood culture positive 1 (2.0)
Cardio-respiratory arrest 1 (2.0)
Cerebral hypoperfusion 1 (2.0)
Dyspnea 1 (2.0)
Enterococcal infection 1 (2.0)
Fat embolism 1 (2.0)
Hematemesis 1 (2.0)
Hematocrit decreased 1 (2.0)
Hemodynamic instability 1 (2.0)
Heart rate increased 1 (2.0)
Hypertension 1 (2.0)
Hypoxic-ischemic encephalopathy 1 (2.0)
Ischemic stroke 1 (2.0)
Joint contracture 1 (2.0)
Leukocytosis 1 (2.0)
Noncardiac chest pain 1 (2.0)
Pneumothorax 1 (2.0)
Postoperative wound infection 1 (2.0)
Renal failure 1 (2.0)
Respiratory tract infection 1 (2.0)
Septic shock 1 (2.0)
Shock 1 (2.0)
Skin infection 1 (2.0)
Splenic hemorrhage 1 (2.0)
Splenic injury 1 (2.0)
Supraventricular tachycardia 1 (2.0)
Tachycardia 1 (2.0)
Traumatic brain injury 1 (2.0)
Traumatic liver injury 1 (2.0)
Wound infection, staphylococcal 1 (2.0)
CTAG, Conformable GORE TAG thoracic endoprosthesis.
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severe injury. Although many overwhelming positive early
reports exist, complications have occurred raising the
need for evaluation of device performance in this disease-
speciﬁc condition.
As previously reported, the mean age of patients
suffering BAI is considerably younger than that being
treated by TEVAR for aneurysmal disease. The mean age
of our cohort was 44.1 years. This is similar to other pub-
lished series on the subject.10 The mortality rate observed
in this cohort, however, was less than expected based on
their ISS score of 33. This may be related to the young
age of this cohort or other aspects of their injuries not
investigated during this study. Correspondingly, the aortic
diameter in these patients is also smaller but appears larger
than that previously reported.11 Device size selection was
based on the CT intimal diameter as dictated by the
instructions for use, however, no guidelines were given
with respect to determining the impact of hypotension
on this measurement. Additional modalities such as intra-
vascular ultrasound were used at the discretion of the
implanting physician to aid in procedural planning.
The original TAG device was designed with an oversiz-
ing window of 6%-22%. The treating physician needed to
account for the degree of hypotension-induced aortic
contraction, orthogonal centerline adjustments, and aortic
curvature so that the appropriately sized device could be
implanted. Small errors in these calculations led to potential
procedural- and device-related complications that exposed
the patients to the life-threatening situation of device
compression.3 Secondary procedures were then required
to remedy the situation.12 In contrast, the redesigned device
has generous oversizingwindows (6%-33%), which allow the
treating physician to choose among several devices for
implantation. Device selection under this design approach
provides a wider margin of variance, thereby reducing the
risks of sizing/implantation complications by the physician.
Analysis of CT scan diameter measurements in this cohort
revealed that 73% of the patients did not meet sizing criteria
for the original TAG device. Fifty-nine percent of patients
needed a smaller device (less than 23mm), and an additional
14% of subjects enrolled were too tapered for the TAG
device sizing guidelines. It should be noted that tapereddevice conﬁgurations accounted for the majority of the
increase in patient applicability and seem most useful in
patients with BAI. Additionally, no adjustments were
made when calculating the aortic diameters to compensate
for hypotension-induced aortic contraction. The impact of
the CTAG device oversizing window cannot be emphasized
enough, as it signiﬁcantly increases the applicability of the
device to the patient population impacted most by blunt
aortic trauma.
The median delay prior to treatment was 21 hours.
This is similar to the report in 1997 of 16 hours (injury
JOURNAL OF VASCULAR SURGERY
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the Surgery of Trauma publication13 and signiﬁcantly less
than 55 hours reported in the subsequent American Asso-
ciation for the Surgery of Trauma study in 2008.1 Whether
this is related to changes in practice patterns, device avail-
ability, or a trend away from delayed repair with endovas-
cular techniques is difﬁcult to determine.
Exclusion criteria was not based on the radius of curva-
ture in this study. As such, device conformability was not
calculated. While it is extremely difﬁcult to quantify the
degree of conformability of a device to the inferior aspect
of the aortic arch, it has been the general perception by
the implanting physicians that this device conforms better
than the previous iteration. Prior publications have empha-
sized the impact of “bird-beaking” on device outcomes.14
There was a decreased number of type I endoleaks reported
in the TAG 08-03 aneurysm study. Type Ia endoleaks
(major and minor) were present in 6.5% of TAG 08-03
patients through 30 days compared with 9.4%, 8.0%, and
12.9% of patients in the original TAG trials (TAG 99-01,
TAG 03-03, and TAG 04-02, respectively). Multifactorial
issues including patient selection, physician experience,
and improved preoperative imaging are also likely causative
factors for this observation, however, enhanced device con-
formability cannot be ignored and was speciﬁcally targeted
as a new design feature with the device.
Speciﬁc design features were engineered into the CTAG
device by altering the fabric and wire components and
were conﬁrmed through computational analysis. The orig-
inal TAG device was prone to device compression when
excessive oversizing or poor conformability existed.3,8
Compression complications with the original TAG device
occurred more commonly with treatments involving blunt
aortic injuries with an overall incidence of 0.4% and occur-
ring at a median and mean follow-up of 9.5 and 76 days,
respectively (range, 0-2190).3 To date, no device compres-
sions have been reported in either of the two trials, and no
compression events have been reported to the company in
over 10,000 implants worldwide suggesting that the new
engineering design has mitigated this problem signiﬁcantly
if not completely.
Revascularization of the left subclavian artery during
TEVAR has been debated ever since its introduction.
Recent recommendations from the SVS,15 state
“.revascularization should be individualized and addressed
expectantly on the basis of anatomy, urgency, and availability
of surgical expertise (GRADE 2, level C).”Of note, only 9%
of patients who required LSCA coverage underwent
planned revascularization, despite 63% having either partial
or complete coverage of their LSCA. No data were avail-
able concerning vertebral imaging in this group of patients.
No patient experienced paraplegia, and the only patient
who developed arm symptoms had a partially covered left
subclavian artery and presented for treatment approxi-
mately 4 months after their procedure. The symptoms
resolved after placement of a left subclavian stent. No other
delayed revascularizations were performed. Subclavian
revascularization is more difﬁcult to perform in the traumapopulation because, in most instances, the cervical spine has
not been cleared prior to the need for repair of the aortic
injury. Given the short coverage length needed for exclu-
sion (generally 10 cm), there appears to be little risk of
inducing paraplegia. To date, there have been only two re-
ported cases of paraplegia associated with TEVAR for BAI
in the literature.16 Although the potential risk of a spinal
cord ischemic complication appears extremely low, other
potential complications remain a concern.
It should be noted that not all devices in the TAG
08-02 study were implanted completely distal to the left
common carotid artery. Despite this, no strokes have
occurred beyond the 30-day follow-up period. The proximal
conﬁguration of the devices does possess partially uncovered
stents that allow perfusion, however, the constraining sleeve
extends into this region and can obstruct ﬂow. It should be
noted that there have been no aortic complications in this
trial, such as retrograde dissection, from the partially uncov-
ered stent of the device on the proximal end. Two cerebral
events were documented during the trial that warrant special
mention. An ischemic stroke was suspected in an elderly
patient; however, the evaluation was limited because the
patient expired from splenic hemorrhage on the ﬁrst
postoperative day. The second patient was diagnosed with
hypoxic-ischemic encephalopathy, which fully resolved after
37 days. The CEC determined that neither of these events
was related to the device.
Finally, there are several criticisms of the study that
should be noted. Although the speciﬁc grading classiﬁca-
tion from Azizzadeh17 was not used, a categorization was
used to denote intimal and nonintimal injuries. The vast
majority of patients were not treated for intimal injuries.
Determination as to whether the patient required treat-
ment was left to the discretion of the treating physician.
The trial was conducted speciﬁcally in this fashion to avoid
controversies in this respect since there is no current stan-
dard of practice. Although it is generally accepted that
grade I injuries can be observed safely, no requirement
was dictated in the trial. There was, however, a restriction
in the ISS, with respect to enrollment in the trial. Those
patients with an ISS of 75 were excluded. An ISS score
of 75 was assigned to any patient with at least one body
region that had an unsurvivable injury or if at least three
body regions had critical injuries. Subjects with an ISS of
75 were excluded from TAG 08-02 to allow for the enroll-
ment of subjects who were likely to survive the endovascu-
lar procedure and provide follow-up. Lastly, the timing of
repair was determined by the treating facility. The mean
length of time from injury to treatment was 21 hours
(range, 3-334). There was a fairly wide range, which is
most likely related to concomitant patient injuries;
however, the reasons for not undergoing immediate repairs
were not tabulated.CONCLUSIONS
The conformable GORE TAG device was speciﬁcally
designed for the treatment of blunt aortic injuries.
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cantly more patients to be treated within the sizing guide-
lines. There have been no reports of device collapse in
clinical studies or commercial use of the device. The
CTAG device appears to be a safe and effective treatment
modality for traumatic aortic transection based on 30-day
outcomes with no device-related serious adverse events.
As a result of these data, in conjunction with prior support-
ing studies, the FDA has approved this device for the treat-
ment of isolated lesions of the descending thoracic aorta.
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